Granted Patent
B2
US 12,291,557 · App. 17/040,317 · Granted May 6, 2025
Chimeric TIM4 receptors and uses thereof
Assignee:
CERO THERAPEUTICS HOLDINGS, INC.
C07K14/705A61K40/11A61K40/31A61K40/32A61K40/4257A61K45/06C07K16/2818C12N5/0636C07K2319/02C07K2319/03
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to chimeric Tim4 receptors, host cells modified to include chimeric Tim4 receptor molecules, and methods of making and using such receptor molecules and modified cells.
Claims (20)
1. A chimeric Tim4 receptor comprising a single chain chimeric protein, the single chain chimeric protein comprising:
a receptor binding domain comprising a Tim4 binding domain;
an intracellular signaling domain comprising a CD28 costimulatory signaling domain and a CD3ζ signaling domain; and
a transmembrane domain positioned between and connecting the receptor binding domain and the intracellular signaling domain.
2. The chimeric Tim4 receptor of claim 1 , wherein the Tim4 binding domain comprises the amino acid sequence of SEQ ID NO:2 or amino acids 25-314 of SEQ ID NO:2.
3. The chimeric Tim4 receptor of claim 1 , wherein the receptor binding domain further comprises an extracellular spacer domain positioned between the Tim4 binding domain and the transmembrane domain.
4. The chimeric Tim4 receptor of claim 3 , wherein the extracellular spacer domain comprises an immunoglobulin hinge region, a hinge region of a type 1 membrane protein, a stalk region of a type II C-lectin, an immunoglobulin constant domain, or a fragment thereof.
5. The chimeric Tim4 receptor of claim 4 , wherein the extracellular spacer domain comprises:
(a) an IgG1, IgG2, IgG3, IgG4, IgA, or IgD hinge region;
(b) a modified IgG4 hinge region comprising the amino acid sequence of SEQ ID NO: 3;
(c) a stalk region of a type II C-lectin selected from CD23, CD69, CD72, CD94, NKG2A, and NKG2D;
(d) a hinge region of a type 1 membrane protein selected from CD8a, CD4, CD28 and CD7; or
(e) an immunoglobulin constant region domain selected from a CH1 domain, a CH2 domain, a CH3 domain, or any combination thereof.
6. The chimeric Tim4 receptor of claim 1 , wherein the transmembrane domain comprises a Tim4, CD27, CD28, CD8, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, or B7-H3 transmembrane domain.
7. The chimeric Tim4 receptor of claim 6 , wherein the transmembrane domain comprises a Tim4 transmembrane domain comprising the amino acid sequence of SEQ ID NO:28, a CD27 transmembrane domain comprising the amino acid sequence of SEQ ID NO:32, a CD28 transmembrane domain comprising the amino acid sequence of SEQ ID NO:29, a 4-1BB transmembrane domain comprising the amino acid sequence of SEQ ID NO:30, an OX40 transmembrane domain comprising the amino acid sequence of SEQ ID NO:31, a CD30 transmembrane domain comprising the amino acid sequence of SEQ ID NO:36, a CD40 transmembrane domain comprising the amino acid sequence of SEQ ID NO:37, a PD-1 transmembrane domain comprising the amino acid sequence of SEQ ID NO:38, an ICOS transmembrane domain comprising the amino acid sequence of SEQ ID NO: 33, a LFA-1 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 35, a CD2 transmembrane domain comprising the amino acid sequence of SEQ ID NO:34, or a CD7 transmembrane domain comprising the amino acid sequence of SEQ ID NO:39, a LIGHT transmembrane domain comprising the amino acid sequence of SEQ ID NO:40, a NKG2C transmembrane domain comprising the amino acid sequence of SEQ ID NO:41, or a B7-H3 transmembrane domain comprising the amino acid sequence of SEQ ID NO:42=.
8. The chimeric Tim4 receptor of claim 1 , wherein the CD28 costimulatory signaling domain comprises the amino acid sequence of SEQ ID NO:4 or 62.
9. The chimeric Tim4 receptor of claim 1 , wherein the transmembrane domain is a CD28 transmembrane domain.
10. The chimeric Tim4 receptor of claim 1 , wherein the CD3ζ signaling domain comprises the amino acid sequence of SEQ ID NO: 63 or 19.
11. The chimeric Tim4 receptor of claim 1 , wherein:
the chimeric Tim4 receptor comprises the amino acid sequence of SEQ ID NO: 69 or amino acids 25-495 of SEQ ID NO:69.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 20, 2024
From: CERO THERAPEUTICS, INC.
To: CERO THERAPEUTICS HOLDINGS, INC.
Reel/Frame 069436/0937 →
Continuity (2)
Provisional Application
62649491
· Mar 28, 2018
References Cited (184)
US 5019368A
· Epstein et al.
· 1991
[cited by applicant]
US 5641863A
· Schreiber et al.
· 1997
[cited by applicant]
US 5641875A
· Schreiber et al.
· 1997
[cited by applicant]
US 5776910A
· Schreiber et al.
· 1998
[cited by applicant]
US 5821071A
· Schreiber et al.
· 1998
[cited by applicant]
US 6068983A
· Schreiber et al.
· 2000
[cited by applicant]
US 6475997B1
· Schreiber et al.
· 2002
[cited by applicant]
US 6630313B2
· Fadok et al.
· 2003
[cited by applicant]
US 8119772B2
· Yang et al.
· 2012
[cited by applicant]
US 8496938B2
· Smith et al.
· 2013
[cited by applicant]
US 8956616B2
· Thorpe et al.
· 2015
[cited by applicant]
US 20030072743A1
· Albert et al.
· 2003
[cited by applicant]
US 20030095962A1
· Ueda et al.
· 2003
[cited by applicant]
US 20030130218A1
· Schreiber et al.
· 2003
[cited by applicant]
US 20060002940A1
· Stevenson
· 2006
[cited by applicant]
US 20060257359A1
· Francois et al.
· 2006
[cited by applicant]
US 20070258897A1
· Devitt et al.
· 2007
[cited by applicant]
US 20080213216A1
· Schreiber et al.
· 2008
[cited by applicant]
US 20110165649A1
· Tyler et al.
· 2011
[cited by applicant]
US 20130071414A1
· Dotti et al.
· 2013
[cited by applicant]
US 20140162290A1
· Watanabe et al.
· 2014
[cited by applicant]
US 20170151281A1
· Wagner et al.
· 2017
[cited by applicant]
US 20170209492A1
· June et al.
· 2017
[cited by applicant]
US 20180186855A1
· Rosenthal
· 2018
[cited by applicant]
US 20180291089A1
· Epstein et al.
· 2018
[cited by applicant]
US 20180319862A1
· Thompson et al.
· 2018
[cited by applicant]
US 20210015865A1
· Corey
· 2021
[cited by applicant]
US 20210024607A1
· Corey et al.
· 2021
[cited by applicant]
US 20210253696A1
· Corey et al.
· 2021
[cited by applicant]
WO WO0168709A1
· 2001
[cited by applicant]
WO WO0185207A2
· 2001
[cited by applicant]
WO WO2005019429A2
· 2005
[cited by applicant]
WO WO2005090573A2
· 2005
[cited by applicant]
WO WO2005097211A2
· 2005
[cited by applicant]
WO WO2013074916A1
· 2013
[cited by applicant]
WO WO2013192294A1
· 2013
[cited by applicant]
WO WO2014031687A1
· 2014
[cited by applicant]
WO WO2014059173A2
· 2014
[cited by applicant]
WO WO2014153114A1
· 2014
[cited by applicant]
WO WO2015066262A1
· 2015
[cited by applicant]
WO WO2015123642A1
· 2015
[cited by applicant]
WO WO2015184228A1
· 2015
[cited by applicant]
WO WO2016019300A1
· 2016
[cited by applicant]
WO WO2016044605A1
· 2016
[cited by applicant]
WO WO2016126608A1
· 2016
[cited by applicant]
WO WO2017019848A1
· 2017
[cited by applicant]
WO WO2017025944A2
· 2017
[cited by applicant]
WO WO2017083700A1
· 2017
[cited by applicant]
WO WO2017205747A1
· 2017
[cited by applicant]
WO WO2017219916A1
· 2017
[cited by applicant]
WO WO2018031419A1
· 2018
[cited by applicant]
WO WO2018064076A1
· 2018
[cited by applicant]
WO WO2018132695A1
· 2018
[cited by applicant]
WO WO2018212770A1
· 2018
[cited by applicant]
WO WO2018220224A1
· 2018
[cited by applicant]
WO WO2019067328A1
· 2019
[cited by applicant]
WO WO2019079529A1
· 2019
[cited by applicant]
WO WO2019086512A1
· 2019
[cited by applicant]
WO WO2019091478A1
· 2019
[cited by applicant]
WO WO2019157440A1
· 2019
[cited by applicant]
WO WO2019191332A1
· 2019
[cited by applicant]
WO WO2019191339A1
· 2019
[cited by applicant]
WO WO2019191340A1
· 2019
[cited by applicant]
WO WO2020223550A1
· 2020
[cited by applicant]
WO WO2021067875A1
· 2021
[cited by applicant]
WO WO2022036265A1
· 2022
[cited by applicant]
WO WO2022036285A1
· 2022
[cited by applicant]
WO WO2022036287A1
· 2022
[cited by applicant]
WO WO2023010097A1
· 2023
[cited by applicant]
Chen, Thomas T., et al. “TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis.” The Journal of experimental medicine 202.7 (2005): 955-965. (Year: 2005).
[cited by examiner]
Park, Daeho, Amelia Hochreiter-Hufford, and Kodi S. Ravichandran. “The phosphatidylserine receptor TIM-4 does not mediate direct signaling.” Current biology 19.4 (2009): 346-351. (Year: 2009).
[cited by examiner]
Genbank Accession No. NP_612388 (2006) (Year: 2006).
[cited by examiner]
Genbank Accession No. NP_848874 (2009) (Year: 2009).
[cited by examiner]
Aderem, “Phagocytosis and the Inflammatory Response,” JID 187(Suppl 2):S340-S345, 2003.
[cited by applicant]
Agaugue et al., “224. Development of Safer & Optimized CAR-T Cells Using Lentiviral Vectors,” Mol. Ther. 23(Suppl. 1):S88, May 2015.
[cited by applicant]
Aggen et al., “Single-chain V(alpha)V(beta) T-cell receptors function without mispairing with endogenous TCR chains,” Gene Therapy 19:365-374, 2012.
[cited by applicant]
Albert et al., “αvβ5 integrin recruits the CrkII-Dock180-Rac1 complex for phagocytosis of apoptotic cells,” Nature Cell Biology 2:899-905, Dec. 2000.
[cited by applicant]
Altman et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes,” Science 274:94-96, 1996.
[cited by applicant]
Arandjelovic et al., “Phagocytosis of apoptotic cells in homeostasis,” Nat. Immunol. 16(9):907-917, Sep. 2015.
[cited by applicant]
Belzile et al., “Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer,” Immuno Targets and Therapy, (7) pp. 1-14, 2018.
[cited by applicant]
Blackburn et al., “Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection,” Nature Immunology 10(1):29-37, Jan. 2009.
[cited by applicant]
Blasius et al., “Intracellular Toll-like Receptors,” Immunity 32:305-315, Mar. 26, 2010. (11 pages).
[cited by applicant]
Burns et al., “A high molecular weight-melanoma associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas,” Cancer Res. 70(8):3027-3033, Apr. 15, 2010.
[cited by applicant]
Castellano et al., “Membrane recruitment of Rac1 triggers phagocytosis,” Journal of Cell Science 113:2955-2961, 2000.
[cited by applicant]
Chen et al., “Fusion Protein Linkers: Property, Design and Functionality,” Adv. Drug Deliv. Rev. 65(10):1357-1369, Oct. 15, 2013.
[cited by applicant]
Chen et al., “TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis,” JEM 202(7):955-965, Oct. 2005. (11 pages).
[cited by applicant]
Colman, “Effects of amino acid sequence changes on antibody-antigen interactions,” Research in Immunology 145(1):33-36, 1994.
[cited by applicant]
Cordoba et al., “The large ectodomains of CD45 and CD148 regulate their segregation from and inhibition of ligated T-cell receptor,” Blood 121(21):4295-4302, 2013.
[cited by applicant]
Delgado Tascón et al., “The granulocyte orphan receptor CEACAM4 is able to trigger phagocytosis of bacteria,” Journal of Leukocyte Biology 97:521-531, Mar. 2015.
[cited by applicant]
Dillon et al., “Annexin V Binds to Viable B Cells and Colocalizes with a Marker of Lipid Rafts upon B Cell Receptor Activation,” The Journal of Immunology 164:1322-1332, 2000.
[cited by applicant]
Dolezal et al., “ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and …
[cited by applicant]
Duclos et al., “Rab5 regulates the kiss and run fusion between phagosomes and endosomes and the acquisition of phagosome leishmanicidal properties in RAW 264.7 macrophages,” Journal of Cell Science 113:3531-3541, 2000.
[cited by applicant]
Engels et al., “Retroviral Vectors for High-Level Transgene Expression in T Lymphocytes,” Human Gene Therapy 14:1155-1168, Aug. 2003.
[cited by applicant]
Fesnak et al., “Engineered T Cells: The Promise and Challenges of Cancer Immunotherapy,” Nature Reviews Cancer 16(9):566-581, Sep. 2016.
[cited by applicant]
Frecha et al., “Advances in the Field of Lentivector-based Transduction of T and B Lymphocytes for Gene Therapy,” Molecular Therapy 18(10):1748-1757, Oct. 2010.
[cited by applicant]
Gerber et al., “Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts,” Am. J. Nucl. Med. Mol. Im…
[cited by applicant]
Green et al., “Mitochondria and Apoptosis,” Science 281(5381):1309-1312, Aug. 1998.
[cited by applicant]
Greenberg et al., “Clustered syk tyrosine kinase domains trigger phagocytosis,” Proc. Natl. Acad. Sci. USA 93:1103-1107, Feb. 1996.
[cited by applicant]
Greenberg, “Programmed cell death: A way of life for plants,” Proc. Natl. Acad. Sci. USA 93:12094-12097, Oct. 1996.
[cited by applicant]
Guest et al., “The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different scFvs and Antigens,” Journal of Immunotherapy 28(3):203-211, May/Jun. 2005.
[cited by applicant]
Hanayama et al., “Identification of a factor that links apoptotic cells to phagocytes,” Nature 417:182-187, May 2002.
[cited by applicant]
Hartt Meyers et al., “TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation,” Nat. Immunol. 6(5):455-464, May 2005.
[cited by applicant]
Hayashi et al., “The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5,” Nature, 410(6832), Apr. 2001, pp. 1099-1103.
[cited by applicant]
Hochreiter-Hufford et al., “Clearing the Dead: Apoptotic Cell Sensing, Recognition, Engulfment, and Digestion,” Cold Spring Harb Perspect Biol 5:a008748, 2013. (21 pages).
[cited by applicant]
Hudecek et al., “Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells,” Clin. Cancer Res. 19(12):3153-31564, 2013.
[cited by applicant]
Hudecek et al., “The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors is Decisive for In Vivo Antitumor Activity,” Cancer Immunol. Res. 3(2):125-135, Feb. 2015.
[cited by applicant]
Hull et al., “The Mononuclear Phagocyte System in Homeostasis and Disease: A Role for Heme Oxygenase-1,” Antioxidants & Redox Signaling 20(11):1770-1788, 2014.
[cited by applicant]
International Search Report and Written Opinion, mailed Aug. 19, 2019, for International Application No. PCT/US2019/024441, 13 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Feb. 6, 2018, for International Application No. PCT/US2017/53553, 13 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Jun. 28, 2019, for International Application No. PCT/US2019/024442, 12 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Jun. 7, 2019, for International Application No. PCT/US2019/024433, 13 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Mar. 25, 2019, for International Application No. PCT/US2018/052297, 10 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed May 29, 2019, for International Application No. PCT/US2019/024435, 12 pages.
[cited by applicant]
Jones et al., “Lentiviral Vector Design for Optimal T Cell Receptor Gene Expression in the Transduction of Peripheral Blood Lymphocytes and Tumor-Infiltrating Lymphocytes,” Human Gene Therapy 20:630-640, Jun. 2009.
[cited by applicant]
June, “Adoptive T cell therapy for cancer in the clinic,” The Journal of Clinical Investigation 117(6): 1466-1476, Jun. 2007.
[cited by applicant]
Kao et al., “Systematic Comparison of the EF-1 Alpha Short (EFS) and Viral Promoters for Gene Modification of Human Primary Cells for Clinical Applications,” Blood 124(21):3497, Dec. 6, 2014. (3 pages).
[cited by applicant]
Khogeer et al., “Antiphosphatidylserine antibodies as diagnostic indicators of antiphospholipid syndrome,” Lupus 24:186-190, 2015.
[cited by applicant]
Kitchen et al., “Engineering Antigen-Specific T Cells from Genetically Modified Human Hematopoietic Stem Cells in Immunodeficient Mice,” PLoS One 4(12):e8208, Dec. 2009.
[cited by applicant]
Kobayashi et al., “TIM-1 and TIM-4 Glycoproteins Bind Phosphatidylserine and Mediate Uptake of Apoptotic Cells,” Immunity 27:927-940, Dec. 2007.
[cited by applicant]
Kochenderfer et al., “Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor,” J. Immunother. 32(7):689-702, 2009.
[cited by applicant]
Krisky et al., “Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications,” Gene Therapy 5:1517-1530, 1998.
[cited by applicant]
Kruskal et al., “Phagocytic Chimeric Receptors Require Both Transmembrane and Cytoplasmic Domains from the Mannose Receptor,” J. Exp. Med. 176:1673-1680, Dec. 1992.
[cited by applicant]
Kuchroo et al., “The TIM Gene Family: Emerging Roles in Immunity and Disease,” Nature Reviews. Immunology 3, No. 6 (May 30, 2003): 454-62, https://doi.org/10.1038/nri1111.
[cited by applicant]
Luo et al., “Development of genetically engineered CD4+ and CD8+ T cells expressing TCRs specific for a M. tuberculosis 38-kDa antigen,” Journal of Molecular Medicine 89:903-913, 2011.
[cited by applicant]
Meyers et al. “TIM-4 is the Ligand for TIM-1, and the TIM-1-TIM-4 Interaction Regulates T Cell Proliferation.” Nature Immunology 6, No. 5 (Mar. 27, 2005): 455-64. https://doi.org/10.1038/ni1185.
[cited by applicant]
Miksa et al., “A novel method to determine the engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester,” J Immunol Methods 342:71-77, 2009.
[cited by applicant]
Misyurin, “Structure and Functions of Main Apoptosis Receptors and Ligands,” Russian Journal of Biotherapy 14(2):23-30, 2015.
[cited by applicant]
Miyanishi et al., “Identification of Tim4 as a phosphatidylserine receptor,” Nature 450:435-439, Nov. 2007.
[cited by applicant]
Moller-Tank et al., “Characterizing Functional Domains for TIM-Mediated Enveloped Virus Entry”, J. Virology, Jun. 2014, 88(12): 6702-6713).
[cited by applicant]
Morgan et al., “Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes,” Science 314(5796):126-129, Oct. 2006.
[cited by applicant]
Morrissey et al., “Chimeric antigen receptors that trigger phagocytosis,” eLife, 2018. (21 pages).
[cited by applicant]
Muller et al., “Spliceosomal Peptide P140 for Immunotherapy of Systemic Lupus Erythematosus: Results of an Early Phase II Clinical Trial,” Arthritis & Rheumatism 58(12):3873-3883, Dec. 2008.
[cited by applicant]
Nakaya, “Research on Molecular Mechanisms of Engulfment of Apoptotic Cells”, The Pharmaceutical Society of Japan 135(8):949-954, 2015.
[cited by applicant]
Nishi et al., “Systematic characterization of deubiquitylating enzymes for roles in maintaining genome integrity,” Nat Cell Biol. 16(10):1016-8, Oct. 2014. (27 pages).
[cited by applicant]
Nishi et al., “Tim4- and MerTK-Mediated Engulfment of Apoptotic Cells by Mouse Resident Peritoneal Macrophages,” Molecular and Cellular Biology 34(8):1512-1520, Apr. 2014.
[cited by applicant]
Ohtsuka et al. “NFAMI, an immunoreceptor tyrosine-based activation motif-bearing molecule that regulates B cell development and signaling.” Proc. Nat. Acad. Sci. 101: 8126-8131, 2004.
[cited by applicant]
Ortiz, et al. “The evolutionary history of the CD209 (Dc-Sign) family in humans and non-human primates,” Genes and Immunity, Jun. 2008, 2008(9), pp. 483-492.
[cited by applicant]
Park et al., “The Phosphatidylserine Receptor TIM-4 Does Not Mediate Direct Signaling,” Current Biology 19:346-351, Feb. 2009. (6 pages).
[cited by applicant]
Penberthy et al., “Apoptotic cell recognition receptors and scavenger receptors,” Immunological Reviews 269:44-59, 2016.
[cited by applicant]
Pfeifer et al., “Gene Therapy: Promises and Problems,” Annu. Rev. Genomics Hum. Genet. 2:177-211, 2001.
[cited by applicant]
Qin, et al. “Prelinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22,” Molecular Therapy: Oncolytics, vol. 11, Dec. 2018, pp. 127-137.
[cited by applicant]
Ravichandran “Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums, ” J. Exp. Med. 207(9):1807-1817, 2017.
[cited by applicant]
Rodriguez-Manzanet et al., “TIM-4 Expressed on APCs Induces T Cell Expansion and Survival,” The Journal of Immunology 180, No. 7 (Apr. 1, 2008): 4706-13, https://doi.org/10.4049/jimmunol.180.7.4706.
[cited by applicant]
Rossi et al., “Genetic therapies against HIV,” Nat. Biotechnol. 25(12):1444-1454, Dec. 2007.
[cited by applicant]
Sánchez-Fueyo et al., “Tim-3 Inhibits T Helper Type 1-mediated Auto- and Alloimmune Responses and Promotes Immunological Tolerance,” Nature Immunology 4, No. 11 (Oct. 12, 2003): 1093-1101, https://doi.org/10.1038/ni987.
[cited by applicant]
Sato et al., “Enhancement of Fcy Receptor-Mediated Phagocytosis by Transforming Mutants of Cbl1,” The Journal of Immunology 163(11):6123-6131, 1999.
[cited by applicant]
Schmitt et al., “T Cell Receptor Gene Therapy for Cancer,” Human Gene Therapy 20:1240-1248, 2009.
[cited by applicant]
Schutters et al., “Phosphatidylserine targeting for diagnosis and treatment of human diseases,” Apoptosis 15:1072-1082, 2010.
[cited by applicant]
Srivastava et al., “Engineering CAR-T Cells: Design Concepts,” Trends Immunol. 36(8):494-502, 2015.
[cited by applicant]
Stone et al., “A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control,” Cancer Immunol. Immunother. 63(11 ): 1163-1176, Nov. 2014 (NIH Public Access Author Man…
[cited by applicant]
Takeshi, et al., “Regulation of Immunity by Toll-like Receptor Functions: Their Physiological and Pathological Roles,” Journal of Gifu Dental Society, 2011?vol. 37?pp. 138-158.
[cited by applicant]
Vallabhapurapu et al., “Variation in human cancer cell external phosphatidylserine is regulated by flippase activity and intracellular calcium,” Oncotarget 6(33):34375-34388, 2015.
[cited by applicant]
Verhoeyen et al., “Chapter 8: Lentiviral Vector Gene Transfer into Human T Cells,” Methods Mol. Biol. 506:97-114, 2009.
[cited by applicant]
Wälchli et al., “A Practical Approach to T-Cell Receptor Cloning and Expression,” PLoS One 6(11):e27930, 2011. (11 pages).
[cited by applicant]
Walseng et al., “A TCR-based Chimeric Antigen Receptor,” Scientific Reports 7: 10713, 2017. (10 pages).
[cited by applicant]
Wang et al., “A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells,” Blood 118(5):1255-1263, Aug. 2011.
[cited by applicant]
Williamson et al., “Abstract A165: Engineering approaches to uncover the mechanism of apoptotic cell clearance by a conserved signaling system,” CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference…
[cited by applicant]
Williamson et al., “Abstract PR15: Engineering phagocytic signaling,” CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, New York, New York, Sep. 25-28, 2016. (4 pages).
[cited by applicant]
Williamson et al., “Cellular reconstitution of apoptotic cell clearance reveals a multi-step phosphorylation mechanism for Draper receptor triggering,” bioRxiv: 1-48, 2017. (58 pages).
[cited by applicant]
Williamson et al., “Spatial control of Draper receptor signaling initiates apoptotic cell engulfment,” J. Cell Biol. 217(11):3977-3992, 2018.
[cited by applicant]
Yang et al. “Calcineurin/nuclear factors of activated T cells (NFAT)-activating and immunoreceptor tyrosine-based activation motif (ITAM)-containing protein (CNAIP), a novel ITAM-containing protein that activates the ca…
[cited by applicant]
Yang et al., “Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition,” Gene Therapy 15:1411-1423, May 22, 2008. (13 pages).
[cited by applicant]
Zaritskaya et al., “New flow cytometric assays for monitoring cell-mediated cytotoxicity,” Expert Review of Vaccines 9(6):601-616, Jun. 2010. (26 pages).
[cited by applicant]
Zhang et al., “Transduction of Human T Cells with a Novel T-Cell Receptor Confers Anti-HCV Reactivity,” PLoS Pathogens 6(7):e1001018, Jul. 2010. (13 pages).
[cited by applicant]
Zhao et al., “Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines,” J. Immunol. 174:(7):4415-4423, Apr. 2005. (25 pages).
[cited by applicant]
Cited By (1)